GENE ONLINE|News &
Opinion
Blog

2022-07-22| Special

Shifting From Counterculture to Clinical Applications, The Problems Psychedelics Face Getting to Market

by Reed Slater
Share To

The clinical application of psychedelics like MDMA, psilocybin, and LSD is gaining support daily. The class of drugs is quickly shedding its stigma as more research demonstrates the promise of treating ever-pervasive mental health disorders like depression, anxiety, and bipolar. Even with a growing acceptance, psychedelic therapies face significant challenges before they have a chance at making it to the market. 

At BIO International Convention in San Diego, five esteemed professionals in the field discussed the hurdles clinical psychedelic development faces before it can benefit the millions of people in need of better mental health treatments. The panel highlighted problems like scalability, clinical limitations, intellectual property issues, and overcoming the stigma of psychedelics.

GO Prime with only $1.49 now

LATEST
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
EVENT
Scroll to Top